Market Newsdesk

Kohl’s Sends Letter to Shareholders Highlighting Collective Strength of the Board

• Kohl’s Directors outmatch the Activists’ slate on relevant expertise and capabilities
• Kohl’s remains open to new ideas that could enhance shareholder value
• Kohl’s Board has overseen a fundamental transformation to accelerate growth and profitability
• Kohl’s urges shareholders to VOTE FOR ALL 12 of the Company’s highly qualified Directors on the BLUE Proxy Card today
• For more information, investors can visit www.KohlsMomentum.com

MENOMONEE FALLS, Wis.–(BUSINESS WIRE)–
Kohl’s Corporation (NYSE:KSS) (“Kohl’s” or the “Company”) today mailed a letter to shareholders detailing the collective strength of its Board of Directors (the “Board”), which has been thoughtfully assembled to incorporate the full range of skills and capabilities required to oversee Kohl’s continued momentum.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210331005977/en/

Kohl’s urges shareholders to protect the value of their investment by voting the BLUE proxy card today FOR ALL 12 of Kohl’s highly qualified nominees. The Company’s Annual Meeting of Shareholders (the “Annual Meeting”) is scheduled to be held on May 12, 2021. Kohl’s shareholders of record as of the close of business on March 24, 2021 will be entitled to vote at the Annual Meeting.

The full text of the letter to shareholders follows.

***

PROTECT THE VALUE OF YOUR INVESTMENT IN KOHL’S – VOTE THE BLUE PROXY CARD TODAY FOR ALL OF KOHL’S HIGHLY QUALIFIED DIRECTOR NOMINEES

Dear Fellow Shareholder,

Your Company’s Board of Directors has overseen a transformation of Kohl’s including the development of our new strategy, which is producing positive results. Since we announced our new strategy in October 2020, we have generated clear business momentum, which has resulted in stock price appreciation of more than 200%, exceeding the S&P 500 by more than 190%.¹

Simply put, Kohl’s Board, working closely with management, has acted decisively to put the Company on a new trajectory to enhance value for shareholders.

Based on the strength of our performance, your Board recently announced the reinstatement of the Company’s quarterly dividend and our share repurchase program, both of which had been temporarily suspended at the outset of the COVID-19 pandemic.

Kohl’s has a diverse, highly experienced Board that is actively engaged in overseeing the execution of our new strategy. Your Board is committed to ensuring company and leadership accountability for delivering growth and improved profitability.

Do not allow a group of activist hedge funds to disrupt our momentum. Please support the Board that has overseen your Company’s recent outperformance by voting your BLUE proxy card TODAY—by telephone, over the Internet or by signing, dating and returning your enclosed BLUE proxy card.

¹ Bloomberg; as of close of trading on March 30, 2021

STRONG BOARD WITH RELEVANT AND COMPLEMENTARY SKILLSETS

SKILL OR EXPERTISE

BENDER

BONEPARTH

BURD

COSSET

FLOYD

GASS

MITCHELL

PRISING

SCHLIFSKE

SHAPIRA

SICA

STREETER

Current or Former Public Company CEO

X

X

X

X

X

Senior Leadership Experience

X

X

X

X

X

X

X

X

X

X

X

X

Public Company Board Experience (other than Kohl’s)

X

X

X

X

X

X

X

X

X

Board Diversity (Gender or Racial/ Ethnic Diversity)

X

X

X

X

X

Retail or Consumer-Facing Industries

X

X

X

X

X

X

X

X

X

X

X

X

Finance, Accounting or Financial Reporting Experience

X

X

X

X

X

X

X

X

X

X

Technology, E-Commerce or Digital Experience

X

X

X

X

X

X

X

X

X

X

Marketing, Public Relations or Brand Management Experience

X

X

X

X

X

X

X

X

X

X

Operations Management Experience

X

X

X

X

X

X

X

X

X

X

Human Capital, Culture or Compensation Experience

X

X

X

X

X

X

X

X

X

YOUR BOARD HAS OVERSEEN A FUNDAMENTAL TRANSFORMATION TO ACCELERATE GROWTH AND PROFITABILITY

Amidst profound changes that are continuing to reshape the retail industry, your Board has acted decisively to ensure Kohl’s is adapting to win in the marketplace, including by:

• Overseeing a successful leadership transition, starting with the appointment of Michelle Gass, our CEO, who has extensive industry expertise, and subsequently supporting the appointment of a new CFO with significant retail expertise. The Board also supported other significant additions to the executive leadership team, each of whom brings deep experience across digital, technology, and retail;

• Providing oversight for significant, targeted investment in our omnichannel and supply chain capabilities, as well as our store and e-commerce experiences to strengthen our competitive positioning;

• Overseeing significant enhancements in our category mix and brand portfolio and supporting new innovative partnerships, such as Sephora and Amazon;

• Refreshing the Board’s skills and perspectives with a focus on e-commerce, retail and consumer experience; and

• Supporting the fundamental transformation of the Company, culminating in our new strategic plan, announced in October 2020, with the goal of accelerating revenue growth and enhancing long-term profitability.

KOHL’S BOARD HAS THE RIGHT SKILLS AND EXPERIENCE TO DRIVE GROWTH

Michael Bender	Committees: Audit, Governance & Nominating Background Highlights: President and CEO of Eyemart Express, LLC; formerly COO of Global eCommerce at Walmart, Inc.   “The game-changing moves Kohl’s is making across its omnichannel platform are fundamentally enhancing the trajectory of our business and positioning Kohl’s for accelerated performance.”
Peter Boneparth	Committees: Governance & Nominating (Chair), Compensation Background Highlights: Senior Advisor to a division of The Blackstone Group, LLP, advising on the retail industry; formerly President and CEO of Jones Apparel Group   “We are committed to ongoing strategic refreshment of our Board so we have the right expertise and capabilities to support long-term success. We have added six new directors with highly relevant skills in the past five years, refreshing half the Board. The diverse skillsets of our Board and management team have helped us capture innovative opportunities to grow our business and create value for shareholders.”
Steven A. Burd	Committees: Governance & Nominating, Compensation Background Highlights: Founder and CEO of Burd Health LLC; formerly Chairman, CEO of Safeway Inc.   “Kohl’s incredibly healthy and profitable store base is a differentiated asset for the Company, with more than 95% of our stores four-wall cash-flow positive, even in 2020 during the pandemic. We will continue to invest in our stores to drive future growth.”
Yael Cosset	Committees: Audit, Governance & Nominating Background Highlights: SVP and Chief Information Officer of The Kroger Co.; formerly Global VP and Chief Digital Officer of The Kroger Co.   “As a Board, we are constantly ensuring that we are customer-focused and taking the right steps to position the Company for long-term success. This is especially true in digital and ecommerce, where the Company has invested extensively to build a strong omnichannel capability.”
H. Charles Floyd	Committees: Audit, Governance & Nominating Background Highlights: Global President of Operations of Hyatt Hotels Corporation   “Kohl’s has always been known for extraordinary customer service and delivering a great experience. As we look ahead, we are completely transforming the customer experience through the products and brands we offer as well as the environments we create.”
Michelle Gass	Background Highlights: Chief Executive Officer of Kohl’s, formerly Chief Merchandising and Customer Officer; previously President, Starbucks Europe, Middle East and Africa and EVP, Marketing and Category   “We are making significant progress towards becoming the leading destination for the active and casual lifestyle. Our business is building momentum, and we have a clear strategy to accelerate the top line with an intense focus on improving profitability. The Board’s leadership and highly relevant experience is invaluable as we continue to drive the necessary change to position us for the future.”
Robbin Mitchell	Committees: Governance & Nominating Background Highlights: Partner & Managing Director on the Fashion & Luxury leadership team at the Boston Consulting Group; formerly held leadership roles at Club Monaco, Ralph Lauren Corporation, Tommy Hilfiger and GFT USA   “I recently joined the Kohl’s Board because this is an exciting time for the Company with a strong strategy in place and significant opportunities ahead. I look forward to leveraging my deep retail apparel experience to help the Company succeed in this area.”
Jonas Prising	Committees: Compensation (Chair), Governance & Nominating Background Highlights: Chairman and CEO of ManpowerGroup; formerly held leadership roles at Electrolux   “The Board’s compensation philosophy is specifically designed to incentivize and motivate our management team to deliver on key business and financial objectives and increase value for all shareholders. Failure to achieve targeted goals has significant consequences, while success is rewarded. For example, in fiscal 2019 our CEO and senior leadership team did not receive any performance-based annual incentives and no merit increases were awarded in March 2020. Our shareholders have consistently shown strong support for our executive compensation, including support from nearly 92% of the votes cast in favor of our executive compensation last year.”
John E. Schlifske	Committees: Audit, Governance & Nominating Background Highlights: Chairman and CEO of The Northwestern Mutual Life Insurance Company   “The Kohl’s Board and management team have been actively transforming and repositioning the business so that we can pursue new opportunities and accelerate revenues and profitability. As a result of this ongoing investment and renewal, we are now poised to significantly increase shareholder value and continue our long track record of returning capital to shareholders through dividends and buybacks.”
Adrianne Shapira	Committees: Audit, Governance & Nominating Background Highlights: Managing Director of Eurazeo Brands (focused on consumer brands): formerly CFO, David Yurman Enterprises, LLC   “The Company has momentum and our Sephora partnership is particularly exciting. This partnership will establish Kohl’s as a leading beauty destination and will drive significant traffic and attract new, younger customers.”
Frank V. Sica Board Chair	Committees: Compensation, Governance & Nominating Background Highlights: Partner, Tailwind Capital; Mr. Sica brings over three decades of experience serving on public company boards in a variety of industries including retail and technology   “This Board has responded effectively to industry challenges by investing for long-term success, with particular investment in digital, mobile, and personalization capabilities to support shifting consumer preferences. With our strong new leadership team in place, the Company is well positioned to grow and win market share from continued retail industry disruption.”
Stephanie A. Streeter	Committees: Audit (Chair), Governance & Nominating Background Highlights: Formerly CEO of Libbey, Inc.   “Kohl’s has a long history of disciplined capital management, with more than two decades of maintaining an investment-grade rating. With a strong focus on ESG, we have driven results the right way. Our unwavering commitment to business integrity is evidenced by the three-time recognition of Kohl’s as a ‘World’s Most Ethical Company’.”

YOUR BOARD OUTMATCHES THE INVESTOR GROUP’S NOMINEES IN KEY SKILLS

Your Board has the right skills and experience to drive continued momentum. The Activist slate, in contrast, lacks key skills and expertise critical for Kohl’s. For example, four of five of the Activists’ nominees have no meaningful digital experience, an area now representing 40% of our business.

Kohl’s Board has broader and deeper experience, while the Activist Investors’ slate has overseen significant value destruction, including four companies which filed for bankruptcy.

	Full Kohl’s Board	5 Kohl’s Directors Targeted by Activists	5 Activist Nominees
Public Company Board Experience	12	5	3
Current or Former Public Company CEO	5	3	1
Retail or Consumer-Facing Industries	12	5	5
Finance, Accounting or Financial Reporting Experience	10	5	2
Technology, E-Commerce or Digital Experience	10	5	2
Marketing, Public Relations or Brand Management Experience	10	4	3
Operations Management Experience	10	4	3

VOTE THE BLUE PROXY CARD TODAY TO PROTECT THE VALUE OF YOUR INVESTMENT

Visit www.kohlsmomentum.com for more information.

We look forward to engaging with you as the Annual Meeting approaches. As always, we appreciate your investment in Kohl’s, and we thank you for your time and consideration.

Very truly yours,

Michael Bender

Peter Boneparth

Steven A. Burd

Yael Cosset

H. Charles Floyd

Michelle Gass

Robbin Mitchell

Jonas Prising

John E. Schlifske

Adrianne Shapira

Frank V. Sica

Stephanie A. Streeter

	YOUR VOTE IS IMPORTANT!
	Please refer to the enclosed BLUE proxy card for information on how to vote by telephone or by Internet, or simply sign and date the BLUE proxy card and return it in the postage-paid envelope provided. If you have any questions, or need assistance in voting
	your shares, please call our proxy solicitor,
	INNISFREE M&A INCORPORATED
	TOLL-FREE, at 1-877-717-3905.

About Kohl’s

Kohl’s (NYSE: KSS) is a leading omnichannel retailer. With more than 1,100 stores in 49 states and the online convenience of Kohls.com and the Kohl’s App, Kohl’s offers amazing national and exclusive brands at incredible savings for families nationwide. Kohl’s is uniquely positioned to deliver against its strategy and its vision to be the most trusted retailer of choice for the active and casual lifestyle. Kohl’s is committed to progress in its diversity and inclusion pledges, and the company’s environmental, social and corporate governance (ESG) stewardship. For a list of store locations or to shop online, visit Kohls.com. For more information about Kohl’s impact in the community or how to join our winning team, visit Corporate.Kohls.com or follow @KohlsNews on Twitter.

Cautionary Statement Regarding Forward-Looking Information

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “anticipates,” “strategy,” “preliminary,” “plans,” or similar expressions to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, which could cause the Company’s actual results to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to, our ability to execute on and realize the benefits of our strategic plan, market conditions beyond our control, including the ongoing and evolving impact of the COVID-19 pandemic, that may negatively impact our stock price vis-à-vis industry analyst expectations and the risks described more fully in Item 1A in the Company’s Annual Report on Form 10-K, which is expressly incorporated herein by reference, and other factors as may periodically be described in the Company’s filings with the SEC. Forward-looking statements relate to the date initially made, and Kohl’s undertakes no obligation to update them.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210331005977/en/

Investor Relations: Mark Rupe, (262) 703-1266, [email protected]

Media: Jen Johnson, (262) 703-5241, [email protected]

Lex Suvanto, (646) 775-8337, [email protected]

KEYWORDS: United States North America Wisconsin

INDUSTRY KEYWORDS: Discount/Variety Men Department Stores Home Goods Family Consumer Fashion Cosmetics Retail Other Consumer Teens Women Parenting Seniors Children Online Retail Baby/Maternity

MEDIA:

Logo

Tenax Therapeutics Reports Fiscal Year 2020 Results and Provides Business Update

MORRISVILLE, N.C.–(BUSINESS WIRE)–
Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the year ended December 31, 2020 and provided a business update.

“Now that the merger with PH Precision Medicine is complete, we have clinical development programs in group one and group two Pulmonary Hypertension patients,” stated Anthony DiTonno, Chief Executive Officer of Tenax, “which represent more than 70% of the overall market.”

“Having acquired the oral formulation rights of Levosimendan from our agreement with Orion, we have set up an open label transition study to determine the dose we will take into Phase 3 trials in 2022. The Phase 2 HELP trial still has patients in the open label phase of the trial. We will be bringing those patients back to their clinics and converting them to the oral dosage form. We believe an oral dosage form will be more convenient to patients and provide more consistent blood levels of drug as opposed to weekly IV administration.”

“With respect to the imatinib program, we continue to make good progress on developing a formulation that will address previous GI-related side effects associated with its oral administration. We remain highly enthusiastic that imatinib, when formulated correctly, will show substantial clinical benefit in the pulmonary arterial hypertension (PAH) patient population, with the potential to be the first disease-modifying therapy for this indication. As we finalize our plans, we will provide additional updates.”

Recent Highlights

• On March 2, 2021, Tenax announced the appointment of four new members to its board of directors: June Almenoff, MD, PhD, Michael Davidson, MD, Declan Doogan, MD, and Stuart Rich, MD. Together, these highly accomplished professionals will provide the Board with significant scientific and commercial perspectives that will prove invaluable as we execute on our long-term corporate strategy. Over the next several months, Tenax expects to advance its two leading pipeline assets into late-stage clinical testing, so the expansion of its board to include such expertise from both the medical community and the pharmaceutical industry could not come at a better time for the company and its shareholders.
• On January 19, 2021, Tenax announced the acquisition of PH Precision Med (PHPM), a privately-held clinical stage biotech company focused on developing imatinib for the treatment of pulmonary arterial hypertension (PAH). The FDA has granted Orphan Drug Designation for imatinib for the treatment of PAH, an indication with a high unmet medical need. The acquisition of PHPM immediately expands Tenax’s pipeline to include a second de-risked Phase 3 ready candidate with the potential to be the first disease modifying treatment of PAH.
• On January 15, 2021, Tenax appointed Stuart Rich, MD, co-founder of PHPM, Chief Medical Officer of Tenax Therapeutics. Dr. Rich currently serves as Professor of Medicine at Northwestern University Feinberg School of Medicine, and Director of the Pulmonary Vascular Disease Program at the Bluhm Cardiovascular Institute. He previously served as FDA Cardio-Renal Advisory Committee Member. His many years of experience as an FDA advisory committee member provides Tenax with an extraordinary knowledge of pulmonary hypertension disease mechanisms and modern regulatory strategies. With his appointment, Tenax is well positioned to maximize the clinical potential of imatinib and advance the clinical development of levosimendan for PH-HFpEF, which together have the potential to address significant unmet needs and large market opportunities.

Financial Results

• Research and development expenses for the year ended December 31, 2020 were $4.6 million, compared to $3.5 million for the year ended December 31, 2019.

• General and administrative expenses for year ended December 31, 2020 were $5.3 million, compared to $5.1 million for the year ended December 31, 2019.

• Net loss for the year ended December 31, 2020 was $9.9 million, or $1.33 per share, compared to a net loss of $8.4 million, or $1.35 per share, for the year ended December 31, 2019.

• Cash, cash equivalents and marketable securities totaled $6.7 million as of December 31, 2020, compared with $5.4 million as of December 31, 2019.

• Management expects that current cash, cash equivalents and marketable securities will be sufficient to fund current operations through the third quarter of 2021.
  

About Tenax Therapeutics

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). Tenax plans to advance a delayed release oral formulation of imatinib, designed to avoid the gastric irritation, into a single pivotal trial pursuant to the 505(b)(2) pathway. For more information, visit www.tenaxthera.com.

About Levosimendan

Levosimendan is a calcium sensitizer that works through a unique triple mechanism of action. It initially was developed for intravenous use in hospitalized patients with acutely decompensated heart failure. It was discovered and developed by Orion Pharma, Orion Corporation of Espoo Finland, and is currently approved in over 60 countries for this indication and not available in the United States. Tenax Therapeutics acquired North American rights to develop and commercialize levosimendan from Phyxius Pharma, Inc.

About Imatinib

Imatinib is an antiproliferative agent developed to target the BCR-ABL tyrosine kinase in patients with chronic myeloid leukemia. The inhibitory effects of imatinib on PDGF receptors and c-KIT suggested that it may be efficacious in PAH. Imatinib reversed experimentally induced pulmonary hypertension and has pulmonary vasodilatory effects in animal models and proapoptotic effects on pulmonary artery smooth muscle cells from patients with idiopathic PAH. In a phase 3 clinical trial imatinib produced significant improvements in exercise capacity, but a high rate of dropouts attributed largely to gastric intolerance prevented regulatory approval.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the Company that involve risks and uncertainties and reflect the Company’s judgment as of the date of this release. The forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to matters beyond the Company’s control that could lead to delays in the clinical study, new product introductions and customer acceptance of these new products; matters beyond the Company’s control that could impact the Company’s continued compliance with Nasdaq listing requirements; the impact of management changes on the Company’s business and unanticipated charges, costs and expenditures not currently contemplated that may occur as a result of management changes; and other risks and uncertainties as described in the Company’s filings with the Securities and Exchange Commission, including in its annual report on Form 10-K filed on March 31, 2021 as well as its other filings with the SEC. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. Statements in this press release regarding management’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

TENAX THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
			Year ended December 31,
			2020					2019
Operating expenses
General and administrative			$	5,307,206				$	5,084,111
Research and development				4,560,724					3,471,153
Total operating expenses				9,867,930					8,555,264
Net operating loss				9,867,930					8,555,264
Interest expense				1,627					–
Other income, net				(18,166	)				(160,901	)
Net loss			$	9,851,391				$	8,394,363
Unrealized loss on marketable securities				528					58
Total comprehensive loss			$	9,851,919				$	8,394,421
Net loss per share, basic and diluted			$	(1.33	)			$	(1.35	)
Weighted average number of common shares outstanding, basic and diluted				7,416,215					6,195,444

TENAX THERAPEUTICS, INC.
CONSOLIDATED BALANCE SHEETS
		December 31, 2020				December 31, 2019
ASSETS
Current assets
Cash and cash equivalents		$	6,250,241			$	4,905,993
Marketable securities			462,687				493,884
Prepaid expenses			82,578				780,952
Total current assets			6,795,506				6,180,829
Right of use asset			58,778				169,448
Property and equipment, net			5,972				6,559
Other assets			8,435				8,435
Total assets		$	6,868,691			$	6,365,271
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable		$	757,856			$	1,661,054
Accrued liabilities			1,240,616				871,341
Note payable			120,491				–
Total current liabilities			2,118,963				2,532,395
Long term liabilities
Lease liability			–				60,379
Note payable			124,166				–
Total long term liabilities			124,166				60,379
Total liabilities			2,243,129				2,592,774
Commitments and contingencies; see Note F
Stockholders’ equity
Preferred stock, undesignated, authorized 4,818,654 shares; See Note E
Series A Preferred stock, par value $.0001, issued 5,181,346 shares; outstanding 210 and 38,606, respectively			–				4
Common stock, par value $.0001 per share; authorized 400,000,000 shares; issued and outstanding 12,619,369 and 6,741,860, respectively			1,262				674
Additional paid-in capital			250,644,197				239,939,797
Accumulated other comprehensive (loss) gain			(70	)			458
Accumulated deficit			(246,019,827	)			(236,168,436	)
Total stockholders’ equity			4,625,562				3,772,497
Total liabilities and stockholders’ equity		$	6,868,691			$	6,365,271

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20210331005976/en/

Investor Contact:

John Mullaly

Managing Director

LifeSci Advisors, LLC

C: 617-429-3548

[email protected]

KEYWORDS: United States North America North Carolina

INDUSTRY KEYWORDS: Pharmaceutical Health Clinical Trials Cardiology

MEDIA:

Logo

CYDY BREAKING NOTICE: ROSEN, A LEADING LAW FIRM, Encourages CytoDyn Inc. Investors with Losses to Secure Counsel Before Important Deadline – CYDY

NEW YORK–(BUSINESS WIRE)–WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytoDyn Inc. (OTC: CYDY) between March 27, 2020 and March 9, 2021, inclusive (the “Class Period”), of the important May 17, 2021lead plaintiff deadline.

SO WHAT: If you purchased CytoDyn securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the CytoDyn class action, go to http://www.rosenlegal.com/cases-register-2060.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 17, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020 founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements touting Leronlimab as a potential treatment for COVID-19 to pump up the CytoDyn’s stock price while executives aggressively sold their shares. The complaint also alleges that CytoDyn engaged in a wrongful scheme whereby Iliad Research and Trading L.P. and other entities related to Iliad’s principal John Fife operated as an unregistered securities dealer for CytoDyn. On this news, the Company’s share price fell $1.14 per share, or 28%, to close at $2.91 on March 8, 2021. On March 9, 2021, CytoDyn shares dropped an additional 19% to close at $2.35, thereby injuring investors further.

To join the CytoDyn class action, go to http://www.rosenlegal.com/cases-register-2060.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210331005980/en/

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

[email protected]

[email protected]

www.rosenlegal.com

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Posted on March 31, 2021 4:44 pm

CTI BioPharma Corp. Announces Proposed Public Offering of Common Stock and Preferred Stock

PR Newswire

SEATTLE, March 31, 2021 /PRNewswire/ — CTI BioPharma Corp. (Nasdaq: CTIC) (“CTI”), a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers, today announced that it intends to offer and sell shares of its common stock and series X¹ preferred stock (the “Series X¹ Preferred”) in an underwritten registered public offering. All of the securities in the proposed offering are to be sold by CTI. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Each share of Series X¹ Preferred will be convertible into 10,000 shares of common stock at the election of the holder, subject to beneficial ownership conversion limits applicable to the Series X¹ Preferred. 

CTI intends to use the proceeds from the proposed sale of its shares of common stock and Series X¹ Preferred Stock for commercialization activities for pacritinib, general working capital and corporate purposes.

Stifel and JMP Securities are acting as joint book-running managers for the offering. BTIG is acting as lead manager for the offering.

The offering is being made pursuant to a registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and subsequently was declared effective by the SEC. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC. Copies of the preliminary prospectus supplement and accompanying prospectus relating to these securities may also be obtained by sending a request to Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery St, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at [email protected], or JMP Securities LLC, 600 Montgomery St, Suite 1100, San Francisco, CA 94111, Attn: Prospectus Department, telephone: 415-835-8900.  

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About CTI BioPharma Corp.
CTI is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI concentrates its efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, CTI is focused on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. In addition, CTI is developing pacritinib for use in the prevention of acute graft versus host disease and in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. CTI is headquartered in Seattle, Washington.

Forward-Looking Statements
Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: whether or not CTI will be able to raise capital through the sale of its securities; the final terms of the proposed offering; the impact of general market, economic, industry or political conditions in the United States or internationally; the satisfaction of customary closing conditions related to the proposed public offering; CTI’s capital position and the sufficiency of its capital to fund its operations in future periods; and those risks more fully discussed in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent quarterly reports on Form 10-Q. There can be no assurance that CTI will be able to complete the proposed public offering on acceptable terms, or at all. CTI will continue to need significant additional capital to fund its operations and may be unable to raise capital when needed, which would force CTI to delay, reduce or eliminate its commercialization activities for pacritinib. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. “CTI BioPharma” and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

CTI BioPharma Investor Contacts:
Maeve Conneighton/Maghan Meyers
+212-600-1902
[email protected]

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-corp-announces-proposed-public-offering-of-common-stock-and-preferred-stock-301260056.html

SOURCE CTI BioPharma Corp.

Posted on March 31, 2021 4:43 pm

Ellomay Capital Announces the Filing of the Annual Report on Form 20-F for 2020

PR Newswire

TEL AVIV, Israel, March 31, 2021 /PRNewswire/— Ellomay Capital Ltd. (NYSE American; TASE: ELLO) (“Ellomay” or the “Company”), a renewable energy and power generator and developer of renewable energy and power projects in Europe and Israel, today announced the filing of its Annual Report on Form 20-F for the year ended December 31, 2020 with the Securities and Exchange Commission.

A copy of the Annual Report on Form 20-F is available to be viewed and downloaded from the Investor Relations section of the Company’s website at http://www.ellomay.com. The Company will provide a hard copy of the Annual Report on Form 20-F, including the Company’s complete audited financial statements, free of charge to its shareholders upon request.

About Ellomay Capital Ltd.

Ellomay is an Israeli based company whose shares are registered with the NYSE American and with the Tel Aviv Stock Exchange under the trading symbol “ELLO”. Since 2009, Ellomay Capital focuses its business in the renewable energy and power sectors in Europe and Israel.

To date, Ellomay has evaluated numerous opportunities and invested significant funds in the renewable, clean energy and natural resources industries in Israel, Italy and Spain, including:

• Approximately 7.9MW of photovoltaic power plants in Spain and a photovoltaic power plant of approximately 9 MW in Israel;
• 9.375% indirect interest in Dorad Energy Ltd., which owns and operates one of Israel’s largest private power plants with production capacity of approximately 860MW, representing about 6%-8% of Israel’s total current electricity consumption;
• 51% of Talasol, which owns a photovoltaic plant with a peak capacity of 300MW in the municipality of Talaván, Cáceres, Spain;
• Groen Gas Goor B.V., Groen Gas Oude-Tonge B.V. and Groen Gas Gelderland B.V., project companies operating anaerobic digestion plants in the Netherlands, with a green gas production capacity of approximately 3 million, 3.8 million and 9.5 million (with a license to produce 7.5 million) Nm3 per year, respectively;
• 83.333% of Ellomay Pumped Storage (2014) Ltd., which is involved in a project to construct a 156 MW pumped storage hydro power plant in the Manara Cliff, Israel.

For more information about Ellomay, visit http://www.ellomay.com.

Contact:

Kalia Weintraub

CFO
Tel: +972-(3)-797-1111
Email: [email protected]

 

View original content:http://www.prnewswire.com/news-releases/ellomay-capital-announces-the-filing-of-the-annual-report-on-form-20-f-for-2020-301260005.html

SOURCE Ellomay Capital Ltd

Posted on March 31, 2021 4:43 pm

McCormick Declares $0.34 Quarterly Dividend

PR Newswire

HUNT VALLEY, Md., March 31, 2021 /PRNewswire/ — The Board of Directors of McCormick & Company, Incorporated (NYSE:MKC) declared a quarterly dividend of $0.34 per share on its common stocks, payable April 26, 2021 to shareholders of record April 12, 2021. McCormick’s current annualized dividend rate of $1.36 per share represents an increase of 10% over the annual dividend of $1.24 per share paid in fiscal year 2020.

This is the 97^th year of consecutive dividend payments by the Company.

About McCormick

McCormick & Company, Incorporated is a global leader in flavor. With over $5 billion in annual sales across 160 countries and territories, we manufacture, market and distribute spices, seasoning mixes, condiments and other flavorful products to the entire food industry including e-commerce channels, grocery, food manufacturers and foodservice businesses. Our most popular brands include McCormick, French’s, Frank’s RedHot, Stubb’s, OLD BAY, Lawry’s, Zatarain’s, Ducros, Vahiné, Cholula, Schwartz, Kamis, DaQiao, Club House, Aeroplane and Gourmet Garden. Every day, no matter where or what you eat or drink, you can enjoy food flavored by McCormick.

Founded in 1889 and headquartered in Hunt Valley, Maryland USA, McCormick is guided by our principles and committed to our Purpose – To Stand Together for the Future of Flavor. McCormick envisions A World United by Flavor where healthy, sustainable and delicious go hand in hand. To learn more, visit www.mccormickcorporation.com or follow McCormick & Company on Twitter, Instagram and LinkedIn.

For information contact:
Corporate Communications: 
Lori Robinson (410) 527-6004 or [email protected]

View original content:http://www.prnewswire.com/news-releases/mccormick-declares-0-34-quarterly-dividend-301260046.html

SOURCE McCormick & Company, Incorporated

Posted on March 31, 2021 4:42 pm

First Solar Completes Sale of North American O&M Business to NovaSource

TEMPE, Ariz., March 31, 2021 (GLOBE NEWSWIRE) — First Solar, Inc. (Nasdaq: FSLR), announced the completion of the previously announced sale of its North American Operations and Maintenance (O&M) business to NovaSource Power Services (“NovaSource”) today.

On closing of the transaction, approximately 270 First Solar O&M associates joined NovaSource. The acquisition makes NovaSource the largest O&M provider globally. NovaSource is a portfolio company of Toronto-based private equity firm Clairvest Group Inc. (TSX: CVG) (“Clairvest”).

About First Solar, Inc.

First Solar is a leading global provider of comprehensive photovoltaic (PV) solar solutions, which use its advanced module and system technology. The company’s integrated power plant solutions deliver an economically attractive alternative to fossil-fuel electricity generation today. From raw material sourcing through end-of-life module recycling, First Solar’s renewable energy solutions protect and enhance the environment. For more information about First Solar, please visit www.firstsolar.com.

About Clairvest

Clairvest’s mission is to partner with entrepreneurs to help them build strategically significant businesses. Founded in 1987 by a group of successful Canadian entrepreneurs, Clairvest is a top performing private equity management firm with over CAD $2.5 billion of capital under management. Clairvest invests its own capital and that of third parties through the Clairvest Equity Partners limited partnerships in owner-led businesses. Under the current management team, Clairvest has initiated investments in 56 different platform companies and generated top quartile performance over an extended period.

Media Reuven Proença First Solar Media [email protected]

Investors Mitchell Ennis First Solar Investor Relations [email protected]